Cargando…

Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China

BACKGROUND: SARS-CoV-2 Omicron (BA.2) has stronger infectivity and more vaccine breakthrough capability than previous variants. Few studies have examined the impact of inactivated vaccines on the decrease of viral RNA levels in individuals with the Omicron variant, based on individuals' continu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Peng, Dang, Bianli, Kang, Wen, Li, Xiaofeng, Wang, Tianping, Li, Ruijuan, Peng, Meijuan, Liu, Yushen, Wang, Linxu, Cheng, Yan, Yu, Suhuai, Wei, Min, Gao, Han, Kang, Wenzhen, Shang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028203/ https://www.ncbi.nlm.nih.gov/pubmed/36960364 http://dx.doi.org/10.3389/fpubh.2023.1107343

Ejemplares similares

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

Heterogeneous changes in mobility in response to the SARS-CoV-2 Omicron BA.2 outbreak in Shanghai
por: Zhang, Juanjuan, et al.
Publicado: (2023)

Pre-Existing Allergies Patients with Higher Viral Load and Longer Recovery Days Infected by SARS-CoV-2 Omicron BA.2 in Shanghai, China, 2022
por: Wen, Ru, et al.
Publicado: (2023)

Risk Factors Associated with the Spatiotemporal Spread of the SARS-CoV-2 Omicron BA.2 Variant — Shanghai Municipality, China, 2022
por: Zheng, Wen, et al.
Publicado: (2023)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study
por: He, Xiaofeng, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022
por: Ling, Yun, et al.
Publicado: (2022)

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
por: Fu, Ziyu, et al.
Publicado: (2023)

Understanding the viral shedding time of Omicron variant BA.2 infection in Shanghai: A population-based observational study
por: Lu, Zhenzhen, et al.
Publicado: (2023)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China
por: Ao, Yuanyun, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
por: Zhang, Dingmei, et al.
Publicado: (2023)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Omicron variant of SARS-COV-2 in Shanghai: Clinical features and inactivated vaccine efficacy in 13,120 elderly patients
por: Li, Jingwen, et al.
Publicado: (2023)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer
por: Yin, Jiaxin, et al.
Publicado: (2022)

Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR
por: Xu, Site, et al.
Publicado: (2022)

First Imported Case of SARS-CoV-2 Omicron Subvariant BA.5 — Shanghai Municipality, China, May 13, 2022
por: Jiang, Hui, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China
por: Wang, Kai, et al.
Publicado: (2023)

Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
por: Ma, Xiaoyu, et al.
Publicado: (2023)

Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
por: Cao, Yunlong, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2
por: Wu, Jun, et al.
Publicado: (2023)

Clinical characteristics and short-term mortality of 102 hospitalized hemodialysis patients infected with SARS-CoV-2 omicron BA.2.2.1 variant in Shanghai, China
por: Bao, Wen Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6dr6tfi4rerqd08je03gib7i3g